Filing Flows › Usana Health Sciences (USNA) › Q2 2026 › vs Q2 2025
Usana Health Sciences (USNA) Q2 2026 vs Q2 2025 (year over year)
Usana Health Sciences's revenue fell $12.6M (-5%) from $236M in Q2 2025 to $223M in Q2 2026.
Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%, net loss $28.0M, operating cash flow $23.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.0% | 3.0% | +6.0 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $223M | $236M | −$12.6M | -5% |
| Other income, net | $1.1M | $2.1M | −$1.0M | -48% |
| Net loss | $28.0M | −$10.4M | $38.4M | — |
| Costs & expenses | $252M | $238M | $14.4M | +6% |
| Operating costs | $243M | $219M | $24.1M | +11% |
| Income tax | $9.1M | $8.4M | $678K | +8% |
| Cost of revenue | $48.3M | $50.2M | −$1.8M | -4% |
| SG&A | $82.3M | $81.9M | $412K | +0.5% |
| Other operating costs | $113M | $87.0M | $25.6M | +29% |
| Operating cash sources | $51.3M | $1.8M | $49.5M | 29× |
| Depreciation & amortization | $7.7M | $7.7M | −$69K | -0.9% |
| Share-based compensation | $3.4M | $3.6M | −$218K | -6% |
| Working capital & other | $40.2M | −$9.6M | $49.8M | — |
| Net loss absorbed | $28.0M | −$10.4M | $38.4M | — |
| Operating cash flow | $23.3M | $12.2M | $11.1M | +91% |
| Free cash flow (OCF − capex) | $20.2M | $7.2M | $13.0M | +180% |
| Capital expenditures | $3.2M | $5.0M | −$1.9M | -37% |
Questions
How much did Usana Health Sciences's revenue grow year over year in Q2 2026?
Usana Health Sciences's revenue fell $12.6M (-5%) from $236M in Q2 2025 to $223M in Q2 2026.